Translate
Edgewise Therapeutics, Inc.
About
32.70USD+0.01 +0.03%
Closed • Updated at 10:03 GMT+00:00Market Cap$3.52B
Volume681.4K
Beta0.57
RSI49.05
Edgewise Therapeutics, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 7 2026
Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications
Mar 10 2026
Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up
Mar 4 2026
Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026
Mar 3 2026
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference
Feb 26 2026
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs
Recent Videos
MESA Extension Study of Sevasemten in Patients With Becker Muscular Dystrophy
Mar 27, 2026
How to Invest in Edgewise Therapeutics Inc (EWTX) Step by Step
Mar 23, 2026
EWTX, Edgewise Therapeutics, Inc., 2026-03-11, stock prices dynamics, stock of the day
Mar 12, 2026
MAJOR UPSIDE : EWTX STOCK ANALYSIS | EDGEWISE THERAPEUTICS STOCK
Jan 24, 2026
Community Chat
Ask AI
Try asking